Plasmodium vivax remains responsive to chloroquine with primaquine treatment regimen: A prospective cohort study from tertiary care teaching hospital in southern India

Kavitha Saravu, Vasudeva Acharya, Krishna Kumar, Rishikesh Kumar

Research output: Contribution to journalArticle

2 Citations (Scopus)


We conducted this prospective study among 110 symptomatic Plasmodium vivax patients attending the Kasturba Hospital, Manipal, India, in order to evaluate their clinico-laboratory profile during July 2007–July 2009. Complications observed among patients were: anaemia (46.4%; 95% confidence interval [CI], 37.08–55.72%); thrombocytopenia (68.2%; 95% CI, 59.5–76.9%); leucopenia (29.1%; 95% CI, 20.61–37.59%); hyperbilirubinaemia (20%; 95% CI, 12.53–27.47%); non-oliguric renal failure (10.9%; 95% CI, 5.08–16.72%); elevated serum transaminases (33.6%; 95% CI, 24.77–42.43%); hypotension (8.2%; 95% CI, 3.07–13.33%); hepatomegaly (27.3%; 95% CI, 18.97–35.63%); and splenomegaly and jaundice in 12.7% (95% CI, 6.48–18.92%). The 99% chloroquine response and zero mortality observed in this study of vivax malaria are encouraging points for practicing physicians.

Original languageEnglish
Pages (from-to)163-164
Number of pages2
JournalTropical Doctor
Issue number3
Publication statusPublished - 01-01-2012


All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this